Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Cue Biopharma, Inc. (CUE) had Normalized Income after Taxes of $-40.67M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$9.29M |
|
$-40.67M |
|
-- |
|
$9.29M |
|
$50.79M |
|
$-41.50M |
|
$0.83M |
|
$-40.67M |
|
$-40.67M |
|
$-40.67M |
|
$-40.67M |
|
$-40.67M |
|
|
Normalized Income after Taxes |
$-40.67M |
$-41.50M |
|
$-41.07M |
|
56.33M |
|
56.33M |
|
$-0.72 |
|
$-0.72 |
|
| Balance Sheet Financials | |
$25.14M |
|
$0.47M |
|
$7.05M |
|
$32.19M |
|
$13.69M |
|
-- |
|
$1.00M |
|
$14.69M |
|
$17.50M |
|
$17.50M |
|
$17.50M |
|
61.82M |
|
| Cash Flow Statement Financials | |
$-36.33M |
|
$0.03M |
|
$10.24M |
|
$48.66M |
|
$22.61M |
|
$-26.05M |
|
$6.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.84 |
|
-- |
|
-- |
|
-- |
|
0.25 |
|
100.00% |
|
-446.86% |
|
-446.86% |
|
-442.19% |
|
-437.97% |
|
-437.97% |
|
$-36.30M |
|
-- |
|
-- |
|
-- |
|
0.29 |
|
-- |
|
9.83 |
|
37.14 |
|
-232.44% |
|
-232.44% |
|
-126.35% |
|
-232.44% |
|
$0.28 |
|
$-0.64 |
|
$-0.65 |
|